Leustatin

Cladribine, the active ingredient in Leustatin, is an antimetabolite presented as an intravenous formulation for IV use. It is employed in the treatment of chronic lymphocytic leukemia, hairy cell leukemia, and relapsing forms of multiple sclerosis, targeting malignant or autoreactive lymphocytes in adult patients.

GNH USA supplies Leustatin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units, and pharmacies worldwide, with established quality‑assured distribution networks and regulatory compliance across EU and other markets.

Cladribine is used in hematologic malignancies and autoimmune disease where lymphocyte proliferation is pathogenic. - Chronic lymphocytic leukemia: reduces malignant B‑cell counts and improves disease control. - Hairy cell leukemia: induces durable remission by depleting abnormal lymphocytes. - Relapsing multiple sclerosis: decreases relapse frequency and slows disability progression.

Cladribine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate upset stomach. - Fever: transient elevations in body temperature. - Lymphopenia: reduced lymphocyte counts. - Headache: occasional mild headache. - Infections: increased susceptibility to common infections.

Serious or Rare Side Effects: - Severe infections: opportunistic or life‑threatening infections. - Autoimmune hepatitis: liver inflammation of immune origin. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Secondary malignancies: rare emergence of new cancers. - Severe neutropenia: markedly low neutrophil counts increasing infection risk.

Cladribine requires careful monitoring and specific safety measures before and during therapy. - Blood count monitoring: perform complete blood counts regularly to detect lymphopenia or neutropenia. - Infection risk assessment: evaluate for active infections and vaccinate appropriately before initiation. - Renal function evaluation: check kidney function as impairment may affect drug clearance. - Contraindication in severe immunosuppression: avoid use in patients with profound immune deficiency. - Contraception: advise women of childbearing potential to use effective contraception during treatment and for a defined period after. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent immunosuppressants: may amplify immunosuppression and infection risk. - Live vaccines: increased chance of vaccine‑derived infection. - Strong CYP450 inhibitors: could raise plasma levels of Cladribine.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., carbamazepine): may alter metabolism. - NSAIDs: potential additive effect on renal function. - Anticoagulants: monitor coagulation parameters due to possible bleeding risk.